Lexicon Pharmaceuticals Provides Clinical Pipeline Update And Reports 2013 Third Quarter Financial Results

THE WOODLANDS, Texas,Nov. 12, 2013/PRNewswire/ --Lexicon Pharmaceuticals, Inc.(Nasdaq:LXRX), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today updated its drug development progress and reported financial results for the three and nine months endedSeptember 30, 2013.

"We have continued to make significant progress in the advancement of our clinical pipeline, highlighted by our announcement of positive top-line results from a phase 2 study of LX4211 in patients with type 2 diabetes and moderate to severe renal impairment," said Dr. Arthur T. Sands, president and chief executive officer of Lexicon.

• LX4211:  LX4211 is a dual inhibitor of sodium-glucose transporters 1 and 2 (SGLT1 and SGLT2).  SGLT1 is primarily responsible for glucose absorption in the gastrointestinal tract and SGLT2 is responsible for most of the glucose reabsorption performed by the kidney.  Lexicon announced positive top-line results from a phase 2 study of LX4211 in patients with type 2 diabetes and moderate to severe renal impairment, and is proceeding with preparations for the initiation of Phase 3 clinical trials of LX4211 in type 2 diabetes.  Lexicon also continues to enroll patients in a phase 2 trial of LX4211 in type 1 diabetes.

• Telotristat etiprate (LX1032):  Telotristat etiprate is an inhibitor of tryptophan hydroxylase that reduces peripheral serotonin production without affecting brain serotonin levels.  Lexicon announced top-line results from a pilot study of telotristat etiprate in patients with mild to moderate ulcerative colitis, and plans to maintain focus on its ongoing Phase 3 program for telotristat etiprate in carcinoid syndrome. Lexicon continues to enroll patients in a pivotal Phase 3 clinical trial of telotristat etiprate in carcinoid syndrome.

• LX1033: LX1033 is an inhibitor of tryptophan hydroxylase that acts locally in the gastrointestinal tract to reduce serotonin production without impacting brain serotonin levels. Lexicon completed enrollment of patients in a Phase 2 clinical trial of LX1033 in diarrhea-predominant IBS, with top-line results expected to be released inNovember 2013.

Revenues:Lexicon's revenues for the three months endedSeptember 30, 2013decreased 36 percent to$0.2 millionfrom$0.4 millionfor the corresponding period in 2012, primarily due to decreases in technology license fees.  For the nine months endedSeptember 30, 2013, revenues decreased seven percent to$0.8 millionfrom$0.9 millionfor the corresponding period in 2012.

Research and Development Expenses:Research and development expenses for the three months endedSeptember 30, 2013increased 32 percent to$25.4 millionfrom$19.2 millionfor the corresponding period in 2012.  The increase was primarily attributable to increases in external clinical and preclinical research and development costs resulting from the advancement of our clinical pipeline, partially offset by decreases in facility costs.  For the nine months endedSeptember 30, 2013, research and development expenses increased 13 percent to$69.4 millionfrom$61.6 millionfor the corresponding period in 2012.

Increase in Fair Value of Symphony Icon Purchase Liability:In connection with the acquisition of Symphony Icon, Lexicon made an initial estimate of the fair value of the liability for the associated base and contingent payments.  Changes in this liability, based on the development of the programs and the time until such payments are expected to be made, are recorded in Lexicon's consolidated statements of operations.  The increase in fair value of the Symphony Icon purchase liability was$1.3 millionand$5.8 millionfor the three months endedSeptember 30, 2013and 2012, respectively, and was$3.1 millionand$10.1 millionfor the nine months endedSeptember 30, 2013and 2012, respectively.

General and Administrative Expenses:General and administrative expenses for the three months endedSeptember 30, 2013increased seven percent to$4.7 millionfrom$4.4 millionfor the corresponding period in 2012.  The increase was primarily attributable to increases in market research, consulting and personnel costs.  For the nine months endedSeptember 30, 2013, general and administrative expenses increased four percent to$13.7 millionfrom$13.1 millionfor the corresponding period in 2012.

Consolidated Net Loss:Net loss for the three months endedSeptember 30, 2013was$31.7 million, or$0.06per share, compared to a net loss of$29.5 million, or$0.06per share, in the corresponding period in 2012.  Net loss for the nine months endedSeptember 30, 2013was$86.7 million, or$0.17per share, compared to a net loss of$85.3 million, or$0.18per share, for the corresponding period in 2012.  For the three and nine months endedSeptember 30, 2013, net loss included non-cash, stock-based compensation expense of$1.8 millionand$5.7 million, respectively. For the three and nine months endedSeptember 30, 2012, net loss included non-cash, stock-based compensation expense of$1.6 millionand$4.9 million, respectively.

Cash and Investments:As ofSeptember 30, 2013, Lexicon had$151.2 millionin cash and investments, as compared to$175.4 millionas ofJune 30, 2013and$223.2 millionas ofDecember 31, 2012.

Lexicon management will hold a conference call to discuss its clinical development progress and financial results for the third quarter of 2013 at11:00 a.m. Eastern TimeonNovember 12, 2013. The dial-in number for the conference call is 888-645-5785 (within the US/Canada) or 970-300-1531 (international). The conference ID for all callers is 97923296. Investors can access a live webcast of the call atwww.lexpharma.com. An archived version of the webcast will be available on the website throughDecember 12, 2013.

Lexicon is a biopharmaceutical company focused on discovering breakthrough treatments for human disease.  Lexicon currently has multiple drug programs in clinical development for diabetes, irritable bowel syndrome, carcinoid syndrome and other indications, all of which were discovered by Lexicon's research team.  Lexicon has used its proprietary gene knockout technology to identify more than 100 promising drug targets.  Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs.  For additional information about Lexicon and its programs, please visitwww.lexpharma.com.

This press release contains "forward-looking statements",includingstatements relating to Lexicon's clinical development of LX4211, telotristat etiprate (LX1032) and LX1033, including characterizations of the results of and projected timing of clinical trials of such compounds, and the potential therapeutic and commercial potential of LX4211, telotristat etiprate (LX1032) and LX1033.  In addition, this press release also contains forward-looking statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information.  All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct clinical development of LX4211, telotristat etiprate (LX1032) and LX1033 and preclinical and clinical development of its other potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements.  Information identifying such important factors is contained under "Risk Factors" in Lexicon's annual report on Form 10-K for the year endedDecember 31, 2012, as filed with the Securities and Exchange Commission.  Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

(In thousands, except per share data)

Revenues:

Collaborative research

$     238

$        214

$     733

$     565

Subscription and license fees

-

158

79

306

Total revenues

238

372

812

871

Operating expenses:

Research and development, including stock-based compensation

of $1,027, $923, $3,379 and $2,875, respectively

25,400

19,192

69,419

61,584

Increase in fair value of Symphony Icon, Inc. purchase liability

1,338

5,844

3,079

10,087

General and administrative, including stock-based compensation

of $723, $669, $2,349 and $2,030, respectively

4,716

4,396

13,709

13,123

Total operating expenses

31,454

29,432

86,207

84,794

Loss from operations

(31,216)

(29,060)

(85,395)

(83,923)

Interest income

39

44

136

158

Interest expense

(492)

(527)

(1,494)

(1,594)

Other income, net

11

4

41

21

Consolidated net loss

$    (31,658)

$  (29,539)

$    (86,712)

$    (85,338)

Consolidated net loss per common share, basic and diluted

$  (0.06)

$  (0.06)

$  (0.17)

$  (0.18)

Shares used in computing net loss attributable to Lexicon Pharmaceuticals, Inc.  per common share, basic and diluted

513,419

490,049

512,980

483,693

(In thousands)

Cash and investments

$        151,210

$     223,208

Property and equipment, net

41,838

42,634

Goodwill

44,543

44,543

Other intangible assets

53,557

53,557

Total assets

299,458

371,778

Deferred revenue

14,090

14,038

Current and long-term debt

22,284

23,451

Other long-term liabilities

37,391

32,283

Accumulated deficit

(986,544)

(899,832)

Total stockholders' equity

185,710

266,678